| Hejaz Sukuk Active ETF (Managed Fund) (SKUK) |
Financials |
$6 |
Quarterly Portfolio Disclosure - December 2024
|
26 Feb 2025 10:15AM |
$1.070 |
$1.050 |
fallen by
1.87%
|
|
| Arovella Therapeutics Limited (ALA) ORDINARY FULLY PAID |
Health Care |
$91 |
Arovella $15m Placement to fund Phase 1
|
26 Feb 2025 10:15AM |
$0.195 |
$0.076 |
fallen by
61.03%
|
|
ALA - Price-sensitive ASX Announcement
Full Release
Key Points
- Arovella received firm commitments for a new placement of approximately $15 million.
- The capital raised allows completion of enrollment for ALA-101 Phase 1 clinical trial.
- Funds will support development of Arovella's solid tumor programs.
- The previous placement announced on 10 January 2025 was withdrawn due to a private investor default.
- Arovella plans to report initial safety and efficacy data from the Phase 1 trial.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Timah Resources Limited (TML) ORDINARY FULLY PAID |
Utilities |
$4 |
Change in Registered Office and Principal Place of Business
|
26 Feb 2025 10:14AM |
$0.041 |
$0.042 |
risen by
2.44%
|
|
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$55 |
1H FY25 Market Update
|
26 Feb 2025 10:14AM |
$0.500 |
$0.240 |
fallen by
52%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- Genetic Signatures Limited provided a market update for 1H FY25.
- The company is focusing on expanding its market presence.
- There are targeted market segments identified for growth.
- The potential market size for testing services is substantial.
- Innovation in genetic testing is a key strategy for the company.
- The update highlights operational enhancements to capture market share.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$55 |
Positive Momentum For The First Half Result
|
26 Feb 2025 10:13AM |
$0.500 |
$0.240 |
fallen by
52%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- 136% improvement in sales during 1H FY25 to $8.5 million
- Gross margin increased to 59% in 1H FY25
- 20% improvement in underlying loss for 1H FY25 to $8.4 million
- Statutory loss of $15.2 million recorded for 1H FY25
- Cash and cash equivalents stood at $40.8 million as of 31 December 2024
- Completion of strategic assessment for automated technology solutions
- Secured first US commercial contract in February 2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Genetic Signatures Limited (GSS) ORDINARY FULLY PAID |
Health Care |
$55 |
Half Yearly Report and Accounts
|
26 Feb 2025 10:12AM |
$0.500 |
$0.240 |
fallen by
52%
|
|
GSS - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales increased to $8.5 million from $3.6 million in the prior half-year.
- Loss of $15.2 million recorded, including $6.8 million in impairment expenses.
- Strategic decision made to cease internal development of the Next Generation Instrument.
- Gross margin improved to 59% due to decreased inventory obsolescence.
- Challenges faced in US product launch due to customer procurement processes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Recce Pharmaceuticals Ltd (RCE) ORDINARY FULLY PAID |
Health Care |
$187 |
Japan Patent Allowance for RECCE Anti-Infectives
|
26 Feb 2025 10:12AM |
$0.445 |
$0.645 |
risen by
44.94%
|
|
RCE - Price-sensitive ASX Announcement
Full Release
Key Points
- Japan Patent Office has allowed a new patent for RECCE anti-infectives.
- Patent Family 4 includes RECCE® 327 and RECCE® 529.
- Patent covers process preparation, use for treating various infections.
- Japan represents the third-largest pharmaceutical market globally.
- Antibiotic resistance market in Japan projected to reach $411.3 million by 2030.
- Recce's anti-infectives aim to address urgent global health problems.
- Global patent protection underscores commitment to innovative therapies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Advance ZincTek Limited (ANO) ORDINARY FULLY PAID |
Materials |
$58 |
Application for quotation of securities - ANO
|
26 Feb 2025 10:06AM |
$0.785 |
$0.920 |
risen by
17.20%
|
|
| Respiri Limited (RSH) ORDINARY FULLY PAID |
Health Care |
- |
Initial Director's Interest Notice
|
26 Feb 2025 10:05AM |
$0.051 |
$0.033 |
fallen by
35.29%
|
|
| Ventia Services Group Limited (VNT) ORDINARY FULLY PAID |
Industrials |
$4,908 |
Change of Director's Interest Notice - Lynne Saint
|
26 Feb 2025 10:04AM |
$4.250 |
$5.930 |
risen by
39.53%
|
|
| Respiri Limited (RSH) ORDINARY FULLY PAID |
Health Care |
- |
Final Director's Interest Notice
|
26 Feb 2025 10:04AM |
$0.051 |
$0.033 |
fallen by
35.29%
|
|
| Meridian Energy Limited (MEZ) ORDINARY FULLY PAID FOREIGN EXEMPT NZX |
Utilities |
$6,225 |
Dividend/Distribution - MEZ
|
26 Feb 2025 10:04AM |
$5.110 |
$4.760 |
fallen by
6.85%
|
|
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$1,189 |
Appendix 4G and Corporate Governance Statement
|
26 Feb 2025 10:02AM |
$3.580 |
$3.220 |
fallen by
10.06%
|
|
| Janus Henderson Sustainable Credit Active ETF (Managed Fund) (GOOD) |
Financials |
$3 |
GOOD - February 2025 Distribution Estimate CPU
|
26 Feb 2025 10:02AM |
$50.660 |
$50.470 |
fallen by
0.38%
|
|
| Telix Pharmaceuticals Limited (TLX) ORDINARY FULLY PAID |
Health Care |
$3,987 |
FDA accepts BLA and grants priority review for Zircaix
|
26 Feb 2025 9:58AM |
$31.140 |
$11.770 |
fallen by
62.20%
|
|
TLX - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA accepted BLA for TLX250-CDx (Zircaix) for kidney cancer imaging.
- TLX250-CDx aims to diagnose and characterize clear cell renal cell carcinoma.
- BLA based on successful Phase 3 ZIRCON study with high sensitivity and specificity.
- FDA granted Priority Review with a PDUFA date of August 27, 2025.
- Potential commercial launch in the U.S. in 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Blackstone Minerals Limited (BSX) ORDINARY FULLY PAID |
Materials |
$86 |
Placement of Shortfall and Cleansing Notice
|
26 Feb 2025 9:57AM |
$0.050 |
$0.051 |
risen by
2%
|
|
BSX - Price-sensitive ASX Announcement
Full Release
Key Points
- Completed placement of Shortfall Shares raising $2.25 million
- A total of 74,946,591 shares placed at $0.03 each
- 600,000 shares issued upon exercising unlisted options
- Cleansing Notice issued under section 708A(5)(e) of the Corporations Act
- Compliance with provisions of Chapter 2M and sections 674 and 674A confirmed
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Farm Pride Foods Limited (FRM) ORDINARY FULLY PAID |
Consumer Staple |
$46 |
Section 708A Cleansing Notice
|
26 Feb 2025 9:56AM |
$0.180 |
$0.200 |
risen by
11.11%
|
|
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$1,189 |
2024 Full Year Results Presentation
|
26 Feb 2025 9:56AM |
$3.580 |
$3.220 |
fallen by
10.06%
|
|
RPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 151% on prior corresponding period to $281 million.
- Strong performance fees of $84.5 million.
- Net inflows of $1.9 billion, up 310% on prior corresponding period.
- Funds under management grew by 64% to $18.0 billion.
- Normalized NPAT of $97.5 million, up 198% on prior year.
- 2H24 dividend of 10 cents per share, 100% franked.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vonex Limited. (VN8) ORDINARY FULLY PAID |
Communication Services |
- |
Application for quotation of securities - VN8
|
26 Feb 2025 9:56AM |
$0.036 |
$0.035 |
fallen by
2.78%
|
|
| Associate Global Partners Limited (APL) ORDINARY FULLY PAID |
Financials |
$10 |
Investor Presentation February 2025
|
26 Feb 2025 9:56AM |
$0.155 |
$0.175 |
risen by
12.90%
|
|
APL - Price-sensitive ASX Announcement
Full Release
Key Points
- FUM grew to $1.721 billion by December 2024.
- Quarterly net inflows reached $289.6 million in Q2 FY25.
- Strong investment performance attributed to large cap strategies.
- AGP's diversification in product offerings enhances market appeal.
- Positive ratings received from Lonsec and Zenith for various funds.
- The company aims to achieve profitability in the near term.
- Continued investments in distribution capabilities and technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Associate Global Partners Limited (APL) ORDINARY FULLY PAID |
Financials |
$10 |
Appendix 4D & HY2025 Financial Statements
|
26 Feb 2025 9:55AM |
$0.155 |
$0.175 |
risen by
12.90%
|
|
APL - Price-sensitive ASX Announcement
Full Release
Key Points
- Silver Lake Resources Limited reported a revenue of $374.4 million for the half-year ending December 31, 2023.
- The gross profit for the same period was $71.2 million.
- Deflector and Rothsay projects produced a total of 56,566 ounces of gold.
- The company mined 412,118 tonnes at an average gold grade of 4.3 g/t.
- Strategic acquisition proposals were highlighted to enhance resource base.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Fiducian Group Limited (FID) ORDINARY FULLY PAID |
Financials |
$370 |
Appendix 3Y - Change of Director's Interest - IS
|
26 Feb 2025 9:55AM |
$10.360 |
$11.730 |
risen by
13.22%
|
|
| Estrella Resources Limited (ESR) ORDINARY FULLY PAID |
Materials |
$68 |
New Discovery at Soru Manganese Prospect
|
26 Feb 2025 9:55AM |
$0.032 |
$0.031 |
fallen by
3.13%
|
|
ESR - Price-sensitive ASX Announcement
Full Release
Key Points
- Surficial alluvial manganese mapped over wide area at the newly discovered Soru Manganese Prospect
- Alluvial manganese deposits are derived from the erosion of secondary manganese forming in nearby hills
- Layer of alluvial and exposed secondary manganese can be traced over a 1.5km by 700m area
- Work in progress to ascertain grade, width and source of the manganese with samples brought back to Australia for analysis
- Environmental License upgrade being sought to allow for trenching and drilling
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Income Asset Management Group Limited (IAM) ORDINARY FULLY PAID |
Financials |
$33 |
IAM announces 32% revenue increase, 32% FUA increase
|
26 Feb 2025 9:55AM |
$0.028 |
$0.035 |
risen by
25%
|
|
IAM - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased 32% to $8.03 million
- Funds Under Administration (FUA) grew 32% to $2.19 billion
- Net loss reduced by 38% to $3.87 million
- New client accounts increased 38% to 2,405
- Trading volumes surged 74% to $2.49 billion
- Cash in bank increased by 38% to $6.51 million
- Capital raise removed $10 million in debt
- IAM is expanding client FUA through adviser networks
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Partners Limited (RPL) ORDINARY FULLY PAID |
Financials |
$1,189 |
2024 Results Release
|
26 Feb 2025 9:53AM |
$3.580 |
$3.220 |
fallen by
10.06%
|
|
RPL - Price-sensitive ASX Announcement
Full Release
Key Points
- Funds under management increased to $18.0 billion, up 64% from 2023.
- Net client inflows of $1.9 billion, a 310% increase compared to the previous year.
- Normalised net profit after tax of $97.5 million, up 198% from the previous year.
- Performance fees of $84.5 million driven by strong performance across diverse strategies.
- Final dividend of 10 cents per share, doubling from the prior year.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.